BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34944844)

  • 1. Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients.
    Asante DB; Morici M; Mohan GRKA; Acheampong E; Spencer I; Lin W; van Miert P; Gibson S; Beasley AB; Ziman M; Calapre L; Meniawy TM; Gray ES
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients.
    Acheampong E; Morici M; Abed A; Bowyer S; Asante DB; Lin W; Millward M; Gray ES; Beasley AB
    J Cancer Res Clin Oncol; 2023 May; 149(5):1941-1950. PubMed ID: 35896898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 Expression with Epithelial Mesenchymal Transition of Circulating Tumor Cells Is Associated with Poor Survival in Curatively Resected Non-Small Cell Lung Cancer.
    Manjunath Y; Upparahalli SV; Avella DM; Deroche CB; Kimchi ET; Staveley-O'Carroll KF; Smith CJ; Li G; Kaifi JT
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31212653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diversity of Epithelial-Mesenchymal Phenotypes in Circulating Tumour Cells from Prostate Cancer Patient-Derived Xenograft Models.
    Hassan S; Blick T; Thompson EW; Williams ED
    Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34206049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients.
    Anantharaman A; Friedlander T; Lu D; Krupa R; Premasekharan G; Hough J; Edwards M; Paz R; Lindquist K; Graf R; Jendrisak A; Louw J; Dugan L; Baird S; Wang Y; Dittamore R; Paris PL
    BMC Cancer; 2016 Sep; 16(1):744. PubMed ID: 27658492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic analysis of heterogeneous subsets of circulating tumour cells from high grade serous ovarian carcinoma patients.
    Asante DB; Mohan GRKA; Acheampong E; Ziman M; Calapre L; Meniawy TM; Gray ES; Beasley AB
    Sci Rep; 2023 Feb; 13(1):2552. PubMed ID: 36781954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin.
    Po JW; Roohullah A; Lynch D; DeFazio A; Harrison M; Harnett PR; Kennedy C; de Souza P; Becker TM
    J Circ Biomark; 2018; 7():1849454418782617. PubMed ID: 30013673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancer.
    Acheampong E; Abed A; Morici M; Spencer I; Beasley AB; Bowyer S; Asante DB; Lomma C; Lin W; Millward M; Gray ES
    Transl Lung Cancer Res; 2022 Mar; 11(3):440-451. PubMed ID: 35399573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep Phenotypic Characterisation of CTCs by Combination of Microfluidic Isolation (IsoFlux) and Imaging Flow Cytometry (ImageStream).
    Ruiz-Rodríguez AJ; Molina-Vallejo MP; Aznar-Peralta I; González Puga C; Cañas García I; González E; Lorente JA; Serrano MJ; Garrido-Navas MC
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34945008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High Specificity in Circulating Tumor Cell Identification Is Required for Accurate Evaluation of Programmed Death-Ligand 1.
    Schehr JL; Schultz ZD; Warrick JW; Guckenberger DJ; Pezzi HM; Sperger JM; Heninger E; Saeed A; Leal T; Mattox K; Traynor AM; Campbell TC; Berry SM; Beebe DJ; Lang JM
    PLoS One; 2016; 11(7):e0159397. PubMed ID: 27459545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC).
    Bergmann S; Coym A; Ott L; Soave A; Rink M; Janning M; Stoupiec M; Coith C; Peine S; von Amsberg G; Pantel K; Riethdorf S
    Oncoimmunology; 2020; 9(1):1738798. PubMed ID: 32391189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
    Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
    Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation System.
    Xu L; Mao X; Imrali A; Syed F; Mutsvangwa K; Berney D; Cathcart P; Hines J; Shamash J; Lu YJ
    PLoS One; 2015; 10(9):e0138032. PubMed ID: 26397728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enrichment with anti-cytokeratin alone or combined with anti-EpCAM antibodies significantly increases the sensitivity for circulating tumor cell detection in metastatic breast cancer patients.
    Deng G; Herrler M; Burgess D; Manna E; Krag D; Burke JF
    Breast Cancer Res; 2008; 10(4):R69. PubMed ID: 18687126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A FACS-based novel isolation technique identifies heterogeneous CTCs in oral squamous cell carcinoma.
    Chauhan A; Pal A; Sachdeva M; Boora GS; Parsana M; Bakshi J; Verma RK; Srinivasan R; Chatterjee D; Maitra A; Ghoshal S
    Front Oncol; 2024; 14():1269211. PubMed ID: 38469233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence.
    Garcia J; Barthelemy D; Geiguer F; Ballandier J; Li KW; Aurel JP; Le Breton F; Rodriguez-Lafrasse C; Manship B; Couraud S; Payen L
    J Vis Exp; 2019 Aug; (150):. PubMed ID: 31475991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastric cancer patients.
    Liu M; Wang R; Sun X; Liu Y; Wang Z; Yan J; Kong X; Liang S; Liu Q; Zhao T; Ji X; Wang G; Wang F; Wang G; Chen L; Zhang Q; Lv W; Li H; Sun M
    Mol Oncol; 2020 Apr; 14(4):865-881. PubMed ID: 31981446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of circulating tumor cells and evaluation of epithelial-mesenchymal transition patterns of circulating tumor cells in ovarian cancer.
    Jie XX; Zhang M; Du M; Cai QQ; Cong Q; Xu CJ; Zhang XY
    Transl Cancer Res; 2022 Aug; 11(8):2636-2646. PubMed ID: 36093536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.